1. Bahn, R., Graves' ophthalmopathy. N Engl J Med, 2010. Issue 326, p. 726.
2. Bartalena, L. et.al., Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.. J Clin Endocrinol Metab, 1983. Volume 56, p. 1139.
3. Burch, H. B. & Wartofsky, L., Graves' ophthalmopathy: current concepts regarding pathogenesis and management.. Endocr Rev, 1993.Volume 14, p. 747.
4. Eckstein, A. K. et.al., Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab, 2006. Issue 91, p. 3464.
5. Li, Y. et al., Clinical outcomes of graves’ ophthalmopathy treated with intensity modulated radiation therapy. Radiation Oncology, 2017. Issue 12, p. 171.
6. Stiebel-Kalish, H et.al, Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.. J Clin Endocrinol Metab, 2009. Volume 94, p. 2708.
7. Tamatea, J. A. U., Conaglen, J. V., & Elston, M. S. (2016). Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population. International Journal of Endocrinology, 2016: 7863867, 1-6.
8. Tanda, M. L., et.al., Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab, 2013. Issue 98, p. 1443.